Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Non-inferiority study of tocilizumab dose-banding versus weight-based dosing in rheumatoid arthritis
2025-522319-41-00Phase 4Authorised
- Sponsor
- Centre Hospitalier Universitaire de Nice
- Start
- Mar 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial of tocilizumab in rheumatoid arthritis (RA) (2 arms), sponsored by Centre Hospitalier Universitaire de Nice. Primary endpoint: Change in DAS28 from baseline to Month 3. Planned start Mar 2026; status: authorised.
02
Drugs
tocilizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2025-522319-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522319-41-00.